AMI finds new partner for Feridex

Article

Advanced Magnetics this month announced a licensing deal with Berlex Laboratories for Feridex,AMI's MR contrast agent for detecting primary and metastatic livertumors. The deal completes a slick piece of horse-trading forAdvanced Magnetics, which

Advanced Magnetics this month announced a licensing deal with Berlex Laboratories for Feridex,AMI's MR contrast agent for detecting primary and metastatic livertumors. The deal completes a slick piece of horse-trading forAdvanced Magnetics, which reacquired Feridex from Sterling Winthroplast year after that company's diagnostic imaging business waspurchased by Hafslund Nycomed.

Advanced Magnetics, of Cambridge, MA, initially licensed rightsto Feridex to Sterling Winthrop in 1993, and AMI received $3.5million in licensing fees from Sterling. A clause in the contractstated that the agreement was not transferable to another party,however, and AMI president Jerome Goldstein exercised that clauselast year after Sterling Winthrop was purchased by Nycomed (SCAN10/26/94 and 8/31/94).

Under the Berlex deal, Advanced Magnetics has received a $5million licensing fee from Berlex in exchange for exclusive marketingrights in the U.S. and Canada. Berlex will pay an additional $5million when Feridex is approved for marketing by the Food andDrug Administration. AMI will also receive payments for manufacturingFeridex as well as a royalty on sales.

AMI filed a new drug application (NDA) with the FDA for Feridexin February 1994. The product has been approved in Europe andwas launched this month by AMI's European marketing partner, Guerbetof France.

Advanced Magnetics also announced a cross-licensing agreementwith Berlex parent Schering AG. The deal gives both parties aworldwide license under each other's patents to their respectivesuperparamagnetic contrast agents.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.